Stockscreener 앱 받기
2.89
16.95%
-0.59
시간 외 거래:
2.92
0.03
+1.04%
전일 마감가:
$3.48
열려 있는:
$3.49
하루 거래량:
1.14M
Relative Volume:
0.21
시가총액:
$12.51M
수익:
$2.07M
순이익/손실:
$-3.53M
주가수익비율:
-2.4569
EPS:
-1.1763
순현금흐름:
$-3.31M
1주 성능:
-54.70%
1개월 성능:
+104.96%
6개월 성능:
+14.68%
1년 성능:
+14.68%
1일 변동 폭
$2.79
$3.69
1주일 범위
$2.79
$6.7499
52주 변동 폭
$1.0266
$8.48
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
명칭
Cyclerion Therapeutics Inc
전화
617-621-7722
주소
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
2.89 | 15.07M | 2.07M | -3.53M | -3.31M | -1.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-20 | 개시 | Truist | Buy |
| 2021-09-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-03 | 개시 | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Rate Hike: Is Cyclerion Therapeutics Incs growth already priced in2026 Historical Comparison & Expert Approved Momentum Ideas - baoquankhu1.vn
Halper Sadeh LLC is Investigating Whether SLNO, FORA, MKC, CYCN are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Alzheimer’s company Korsana heads to NASDAQ via merger: Deals Report - BioCentury
CYCN stock is soaring 150% pre-market today — what is fueling the rally? - MSN
CYCN PE Ratio & Valuation, Is CYCN Overvalued - Intellectia AI
If You Invested $1,000 in Cyclerion Therapeutics Inc (CYCN) - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm
Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) - Sahm
Korsana Biosciences and Cyclerion Therapeutics Announce All-Stock Merger and $380 Million Financing - Global Legal Chronicle
Monteverde & Associates Investigates Cyclerion Therapeutics Merger - National Today
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
CYCN Plunges 17% After Merger Announcement: What’s Next for Cyclerion and Korsana? - Bitget
Cyclerion and Korsana Tie the Knot with a New Merger Strategy - StocksToTrade
Cyclerion Therapeutics Merger Sparks Investor Uncertainty - timothysykes.com
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? - Barchart.com
Korsana boosts Alzheimer’s work with reverse merger, $380M financing - BioWorld News
Cyclerion Therapeutics and Korsana Biosciences Announce $380M Merger to Advance Alzheimer’s Treatment KRSA-028 - Minichart
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSENSA), Urgent.ly, Inc. (OTC MarketsULYX), UniFirst Corporation (NYSEU - Supply Chain Digital Magazine
12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
Cyclerion Therapeutics, Inc. (CYCN) stock price, news, quote and history - Yahoo Finance UK
Cyclerion Therapeutics Merges with Korsana Biosciences in New Agreement - El-Balad.com
Korsana takes its brain shuttle tech public via reverse merger with Cyclerion - FirstWord Pharma
Ademi LLP Investigates Whether Cyclerion Therapeutics Inc. Is Obtaining a Fair Price for Public Shareholders - news.futunn.com
Korsana Biosciences and Cyclerion Therapeutics to Merge, Operate Under Korsana Name - Contract Pharma
Cyclerion Therapeutics to Merge with Korsana Biosciences - TipRanks
Cyclerion Therapeutics: $380 Million Financing To Merge With Korsana Biosciences And Advance Alzheimer’s Pipeline - Pulse 2.0
Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana, $380M PIPE backing - Stock Titan
Cyclerion to Merge With Korsana; $380 Million PIPE, CVRs and Lock-Ups Support Deal - TradingView
Korsana Biosciences to go public via Cyclerion (CYCN) reverse merger and $380M PIPE - Stock Titan
Korsana Taps Cyclerion For $380M Public Listing In Boston - Hoodline
Best Pharmaceutical Stocks To Follow NowApril 1st - MarketBeat
Promising Medical Stocks To ConsiderApril 1st - MarketBeat
Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing - MSN
Cyclerion provides public listing vehicle for Korsana in $380M deal - The Business Journals
Cyclerion Therapeutics, Inc. (CYCN) Stock: Skyrockets 324% on Blockbuster Korsana Merger Backed by Wall Street's Biggest Names - parameter.io
CYCN Stock Explodes 313% on April 1 After Cyclerion-Korsana Merger Deal for Alzheimer's Pipeline - International Business Times Australia
Crude Oil Down Over 1%; ISM Manufacturing PMI Rises In March - Benzinga
Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining? - Investorideas.com
Cyclerion Therapeutics, Korsana Biosciences enter merger agreement - TipRanks
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire
Cyclerion Therapeutics (CYCN) Stock Jumps 160% Following Korsana Biosciences Merger Announcement - MEXC Exchange
Trending Stocks Today | Cyclerion Therapeutics Shoots up 322.9% - Moomoo
Cyclerion Therapeutics and Korsana Biosciences To Merge - citybiz
Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing - Benzinga
Cyclerion Therapeutics surges as it agrees to merge with Korsana Biosciences in a deal backed by a large private financing - Quiver Quantitative
Dow Jumps Over 200 Points; Nike Shares Tumble After Q3 Results - Benzinga
Cyclerion Therapeutics (CYCN) Stock Surges 160% on Korsana Merger Deal - MEXC
Financial Uncertainty Looms as CYCN Faces Market Changes - StocksToTrade
Alzheimer's-focused Korsana uses Cyclerion merger to go public - Fierce Biotech
Cyclerion Therapeutics Inc (CYCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
1.75%
자본화:
|
볼륨(24시간):